ING Groep NV Sells 52,280 Shares of Regeneron Pharmaceuticals, Inc. $REGN

ING Groep NV trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.0% during the fourth quarter, HoldingsChannel reports. The fund owned 56,597 shares of the biopharmaceutical company’s stock after selling 52,280 shares during the quarter. ING Groep NV’s holdings in Regeneron Pharmaceuticals were worth $43,686,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the last quarter. Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Entrust Financial LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $32,000. MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 15 shares during the last quarter. Finally, Torren Management LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $38,000. 83.31% of the stock is owned by institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on REGN shares. Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Royal Bank Of Canada reduced their price target on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating on the stock in a research report on Monday, May 18th. Finally, Sanford C. Bernstein reduced their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ REGN opened at $635.45 on Friday. The company has a market capitalization of $67.18 billion, a P/E ratio of 15.48, a price-to-earnings-growth ratio of 1.40 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 52-week low of $485.00 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company’s 50 day moving average price is $706.93 and its 200-day moving average price is $742.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $8.22 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.